Shares Magazine
$14.71+0.29 (+2.05%)31 Mar 2025, 18:54
Jump to:
Organon & CO Fundamentals
| Company Name | Organon & CO | Last Updated | 2025-03-31 |
|---|---|---|---|
| Industry | Drug Manufacturers - General | Sector | Healthcare |
| Shares in Issue | 257.950 m | Market Cap | $3.79 bn |
| PE Ratio | 4.33 | Dividend per Share | $1.12 |
| Dividend Yield | 7.77 | Dividend Cover | 2.97 |
| EPS | $3.33 | EPS Growth (%) | -0.13 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.6778 | Debt Equity Ratio | 18.7712 |
| Asset Equity Ratio | 27.7564 | Cash Equity Ratio | 1.4301 |
| Quick Ratio | 0.7480 | Current Ratio | 1.60 |
| Price To Book Value | 7.8740 | ROCE | 0 |
Organon & CO Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|---|---|---|---|---|
| Prelim | 2025-02-21 | 2025-03-13 | USD | 0.2800 | |
| Interim | 2024-11-12 | 2024-12-12 | USD | 0.2800 | |
| Interim | 2024-08-16 | 2024-09-12 | USD | 0.2800 | |
| Interim | 2024-05-10 | 2024-06-13 | USD | 0.2800 | |
| Prelim | 2024-02-23 | 2024-03-14 | USD | 0.2800 | |
| Interim | 2023-11-10 | 2023-12-14 | USD | 0.2800 | |
| Interim | 2023-08-17 | 2023-09-14 | USD | 0.2800 | |
| Interim | 2023-05-12 | 2023-06-15 | USD | 0.2800 | |
| Prelim | 2023-02-24 | 2023-03-16 | USD | 0.2800 | |
| Interim | 2022-11-10 | 2022-12-15 | USD | 0.2800 | |
| Interim | 2022-08-12 | 2022-09-15 | USD | 0.2800 | |
| Interim | 2022-05-13 | 2022-06-16 | USD | 0.2800 |
Organon & CO Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $1.17 bn | $1.18 bn | $1.02 bn |
| Intangible Assets | $6.09 bn | $5.14 bn | $5.25 bn |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $8.75 bn | $7.55 bn | $7.02 bn |
| Stocks | $1.32 bn | $1.31 bn | $1.00 bn |
| Debtors | 0 | 0 | 0 |
| Cash & Equivalents | $675.00 m | $693.00 m | $706.00 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $13.10 bn | $12.06 bn | $10.96 bn |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $2.72 bn | $2.92 bn | $2.51 bn |
| Creditors after 1 year | $9.91 bn | $9.21 bn | $9.34 bn |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $12.63 bn | $12.13 bn | $11.85 bn |
| Net assets | $472.00 m | -$70.00 m | -$892.00 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $3.00 m | $3.00 m | $3.00 m |
| Share Premium | $108.00 m | $25.00 m | 0 |
| Profit / Loss | $807.00 m | $673.00 m | $1.12 bn |
| Other Equity | $472.00 m | -$70.00 m | -$892.00 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | $472.00 m | -$70.00 m | -$892.00 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.95 | 0 | 0 |
| Debt-to-Equity | $18.77 | 0 | 0 |
| Assets / Equity | 27.7564 | 27.7564 | 27.7564 |
| Cash / Equity | 1.4301 | 1.4301 | 1.4301 |
| EPS | $3.78 | $4.36 | $4.08 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | $939.00 m | $799.00 m | $858.00 m |
| Cashflow before financing | $571.00 m | $230.00 m | $425.00 m |
| Increase in Cash | -$18.00 m | -$13.00 m | -$31.00 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $6.40 bn | $6.26 bn | $6.17 bn |
| Cost of sales | $2.69 bn | $2.52 bn | $2.29 bn |
| Gross Profit | $3.71 bn | $3.75 bn | $3.88 bn |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | $807.00 m | $673.00 m | $1.12 bn |
Organon & CO Company Background
| Sector | Healthcare |
|---|---|
| Activities | Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio. |
| Latest Interim Date | 6 Aug 2024 |
| Latest Fiscal Year End Date | 13 Feb 2025 |
Organon & CO Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-06-07 | Ms. Carrie S. Cox | Director |
| 2025-02-20 | Mr. Matthew M. Walsh | Chief Financial Officer |
| 2024-06-07 | Ms. Rochelle B. Lazarus | Director |
| 2024-06-07 | Ms. Shalini Sharp | Director |
| 2024-06-07 | Mr. Robert A. Essner | Director |
| 2024-06-07 | Dr. Helene D. Gayle, M.D. | Director |
| 2024-06-07 | Ms. Cynthia M. Patton | Director |
| 2023-05-04 | Ms. Geralyn S. Ritter | Head of Ext. Affairs and ESG |
| 2021-05-07 | Ms. Rita A. Karachun | Director |
| 2024-06-07 | Ms. Grace Puma Whiteford | Director |
| 2024-11-07 | Dr. Juan Camilo Arjona Ferreira, M.D. | Head of R&D & CMO |
| 2023-06-09 | Ms. Fatima Ma. Francisco | Director |
| 2024-06-07 | Dr. Alan Ezekowitz, D.Phil.,MB.Ch.B. | Director |
| 2021-05-07 | Ms. Caroline Litchfield | Director |
| 2025-02-20 | Ms. Rachel A. Stahler | Chief Information Officer |
| 2025-02-20 | Mr. Kevin Ali | Director, Chief Executive Officer |
| 2024-09-03 | Ms. Kathryn DiMarco | Corporate Controller |
| 2025-02-20 | Mr. Aaron Falcione | Chief Human Resources Officer |
| 2024-09-03 | Ms. Susanne Fiedler, PhD | Chief Commercial Officer |
| 2023-05-04 | Dr. Sandra Milligan, J.D. | Head of Research & Development |
| 2025-02-20 | Mr. Joseph T. Morrissey, Jr | Head of Manufacturing |
| 2025-02-20 | Mr. Vittorio Nisita | Head of Global Business Svcs |
| 2022-05-04 | Ms. Deborah H. Telman | EVP GC & Corporate Secretary |
| 2024-06-07 | Ms. Deborah R. Leone | Director |
| 2024-06-07 | Ms. Martha E. McGarry | Director |
| 2024-06-07 | Dr. Phillip Ozuah, M.D.,PhD | Director |
| 2024-05-04 | Mr. Kirke Weaver | Gen. Counsel & Corp. Secy. |
| 2021-05-07 | Mr. Jon Filderman | Director |
Organon & CO Contact Details
| Company Name | |
|---|---|
| Address | |
| Telephone | |
| Website | https://www.organon.com |
Organon & CO Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Aston Martin Lagonda Global Holdings PLC | 69.85 | 7.05 |
| British American Tobacco PLC | 3,182.00 | 1.86 |
| Moonpig Group PLC | 210.00 | 1.69 |
| Severn Trent PLC | 2,531.00 | 1.40 |
| Harbour Energy PLC | 210.30 | 1.40 |
| Imperial Brands PLC | 2,865.00 | 1.38 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Pets AT Home Group PLC | 216.40 | -8.46 |
| Molten Ventures PLC | 256.50 | -7.73 |
| Close Brothers Group PLC | 278.20 | -7.20 |
| International Consolidated Airlines Group S.A. | 260.80 | -6.62 |
| Raspberry Pi Holdings PLC | 466.60 | -6.27 |
| Mobico Group PLC | 58.15 | -6.06 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.